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Available online 9 September 2016Themembrane-associated protein CD36, now officially designated as SR-B2, is present in various tissues and fulfills
multiple cellular functions. In heart and muscle, CD36 is the main (long-chain) fatty acid transporter, regulating
myocellular fatty acid uptake via its vesicle-mediated reversible trafficking (recycling) between intracellular
membrane compartments and the cell surface. CD36 is subject to various types of post-translational modification.
This review focusses on the role of thesemodifications in further regulation of myocellular fatty acid uptake.
Glycosylation, ubiquitination and palmitoylation are involved in regulating CD36 stability, while phosphor-
ylation at extracellular sites affect the rate of fatty acid uptake. In addition, CD36 modification by O-linked
N-acetylglucosamine may regulate the translocation of CD36 from endosomes to the cell surface. Acetylation of
CD36 has also been reported, but possible effects on CD36 expression and/or functioning have not yet been
addressed. Taken together, CD36 is subject to a multitude of post-translational modifications of which their
functional implications are beginning to be understood. Moreover, further investigations are needed to disclose
whether these post-translational modifications play a role in altered fatty acid uptake rates seen in several
pathologies of heart and muscle. This article is part of a special issue entitled: The role of post-translational
protein modifications on heart and vascular metabolism edited by Jason R.B. Dyck and Jan F.C. Glatz.




Cardiac fatty acid uptake1. Introduction
CD36 (cluster of differentiation 36) is a versatile transmembrane
protein. It is a member of the family of class B scavenger receptors
(i.e., scavenger receptors with two transmembrane domains), which
also includes scavenger receptor-B1 (SR-B1) that is involved in binding
of low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
particles, and scavenger receptor LIMP2 (SR-B3), which functions in
lysosomal protein sorting. CD36, now officially designated as scavenger
receptor B2 (SR-B2) [1], is ubiquitously expressed in various tissues and
binds several, mostly lipid-related ligands such as oxidized LDL particles,
(long-chain) fatty acids, collagens, thrombospondin-I, apoptotic cells,
and phospholipids [2]. As a result, CD36 plays a crucial role in numerous
physiological processes including immune system responses, removal of
apoptotic and necrotic cells, regulation of angiogenesis, and scavengingN-succinimidyl oleate; AMPK,
sive rats; O-GlcNAc, O-linked
tein kinase C; PAT, palmitoyl-
le of post-translational protein
by Jason R.B. Dyck and Jan F.C.
latz).of oxidized LDL. These functions are carried out in a tissue-specific
manner.
In cardiac and skeletal muscle, CD36 is the predominant protein
involved in both facilitating and regulating the cellular uptake of
(long-chain) fatty acids. Although this transport function of CD36 had
already been discovered in adipocytes in the early nineties [3], and
immediately thereafter in heart and muscle [4], the molecular mecha-
nism by which CD36 facilitates the transport of fatty acids across the
cell membrane is only beginning to be unraveled. The topography of
CD36 is not compatible with its functioning as a membrane pore for
fatty acids. Therefore, CD36 does not act as a truemembrane ‘transporter’
(such as, for instance, GLUT proteins act as transporter of glucose across
the membrane), but facilitates the transmembrane transport of fatty
acids [5]. Nevertheless, for convenience, CD36 is commonly referred to
as ‘fatty acid transporter’.
Insight into the structure and functioning of CD36 was recently
obtained from the crystal structure of its family member SR-B3/LIMP-2
[6] and further elaborated by Pepino and co-workers [7]. CD36 has two
membrane spanning regions surrounding a large extracellular loop that
contains a large hydrophobic cavity traversing the entire length of the
molecule (Fig. 1). This cavity is considered to serve as a tunnel through
which hydrophobic ligands (including cholesterol(esters) and fatty
acids) are delivered from the extracellular space to the outer leaflet of










































Fig. 1. Schematic presentation of the putative CD36 topology and known post-translational modifications. CD36 (SR-B2) has two transmembrane domains, with the small cytoplasmic tails being
palmitoylated. The COOH terminus also has two ubiquitination sites. The large extracellular loop contains 10N-linked glycosylation sites and two phosphorylation sites. The localization of the O-
GlcNAcylation site is not yet known. Disulfide bonds between the extracellular cysteines are shown. The shaded area designates a hydrophobic pocket that is involved in ligand binding and serves
as a tunnel throughwhich ligands are delivered from the extracellular space to the external leaflet of the phospholipid bilayer of themembrane. Predictions of the three-dimensional structure of
CD36 have been presented by others [6–8]. Arrowheads and numbers indicate the approximate amino acid residues. Modified from ref. [5], with permission.
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uptake, lysine residues bordering this pocket may interact with fatty
acids through electrostatic interactions with the fatty acid-carboxylic
group [9]. After entering the phospholipid bilayer of the membrane and
translocation to the inner leaflet, presumably by a ‘flip-flop’ mechanism
[10], desorption of the fatty acids into the intracellular compartment is
facilitated by cytoplasmic fatty acid-binding protein (FABP) [5].
The first evidence for a major contribution of CD36 to bulk fatty acid
uptake in muscles came from studies using the nucleophilic long-chain
fatty acid derivative sulfo-N-succinimidyl oleate (SSO) [11,12]. SSO
covalently binds to CD36 via Lys164 in the hydrophobic cavity thereby
impairing CD36-mediated fatty acid uptake [9]. This SSO–CD36
binding at the cell surface appears to be specific, as other putative
plasmalemmal fatty acid transporters (e.g., plasma membrane-fatty
acid binding protein and members of the fatty acid transport protein
family) are not labeled by this compound [9,13]. On the other hand, it was
reported that in macrophages, SSO may also exert inhibitory effects on
intracellular lipid metabolism independently of CD36 [14]. Conclusive
evidence was obtained in studies with CD36-null mice, which also
revealed the quantitative importance of CD36 for fatty acid utilization
by mammalian tissues. These experiments showed that N40% and
N70% of fatty acid uptake is mediated by CD36 in oxidative muscle
[15] and heart [16], respectively. Recently, using an inducible and
cardiomyocyte-specific CD36-null mouse model, the relevance of
CD36 specifically for cardiac long-chain fatty acid uptake has been
confirmed [17].
The role of CD36 in myocellular fatty acid utilization goes further
than only serving as a facilitative transporter whereby the rate of trans-
membrane fatty acid transport is dependent solely on its presence in the
membrane and the fatty acid gradient between the extracellular milieu
and the myocellular cytoplasm. Thus, it has been well-established thatwithin the overall processes of fatty acid uptake and subsequentmetabo-
lism, CD36 presents themajor rate-controlling site, making it possible for
myocytes tomaintain low intracellular fatty acid levels even at physiolog-
ically high extracellular fatty acid concentrations [11]. The underlying
molecular mechanism is based on the finding that CD36 is present not
only at the cell surface, where it exerts its transport function, but also in
intracellular storage sites, identified as endosomes. CD36 can migrate
between both locations by means of vesicular transport along exocytotic
and endocytotic pathways. A net translocationof CD36 to the sarcolemma
is induced by several physiological stimuli, most notably, elevated
circulating insulin levels and an increase in contractile activity
whereupon, as a consequence, myocellular fatty acid uptake is
increased. Insulin-induced CD36 translocation requires activation of the
phosphatidylinositol-3-kinase–Akt2 signaling axis, and contraction-
induced CD36 translocation is dependent on activation of AMP-
activated kinase (AMPK) [5].
Various post-translational modifications have been reported to
impact on CD36 and CD36 functioning and, in specific cases, have
been related to malfunctioning of CD36 in disease. These modifications
include glycosylation, acetylation, phosphorylation, palmitoylation, and
ubiquitination. For each of these modifications, we will discuss along-
side the existing literature the possible consequences for the regulation
of fatty acid uptake in heart and muscle and, when data is available,
specifically on the regulation of intracellular CD36 translocation.
2. Glycosylation of CD36
CD36 has a predictedmolecularmass of 53 kDa, but in rodentmuscle
and heart the actual mass of this protein amounts to 88 kDa [3]. The
difference is due mainly to extensive glycosylation. Rat CD36 has 10
potential glycosylation sites, and 8 of these are conserved between rat
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the extracellular loop and indeed were observed to be glycosylated
(Fig. 1). Classical N-linked glycosylation at asparagine residues occurs
within the endoplasmic reticulum and the Golgi, and leads to the stable
coupling of complex oligosaccharide structures to proteins. Glycosyla-
tion is common to many extracellular and secretory proteins, and is
critical for correct folding, stability, transport to the cell surface, and
function of proteins [18]. Glycosylation of CD36 is necessary for proper
folding and trafficking to the plasmamembrane [19]. Yet there is redun-
dancy, as partially glycosylated CD36mutants have been identified that
also were properly distributed to the cell surface [19]. Remarkably, the
exact glycosylation pattern did not matter in this respect. However,
these glycosylation site mutants suffered from low expression levels.
Furthermore, ligand recognition was not affected by alterations in the
glycosylation pattern, as established for binding of CD36 to modified
low-density lipoprotein [19]. With respect to the dynamic regulation
of CD36 glycosylation, the gastrointestinal-derived hormone glucagon-
like peptide-2 has been reported to increase the glycosylation of CD36
with an accompanying increase in the luminal absorption of fatty
acids within hours [20]. However, the mechanism by which CD36
glycosylation leads to increased fatty acid absorption is not known.
Hence, whether the fatty acid transport function of CD36 itself is altered
by differences in glycosylation, is not known.
In spontaneously hypertensive rats (SHR), CD36 is mutated at mul-
tiple sites, themutations ofwhich have been proposed to be responsible
for the reduced cardiac fatty acid uptake seen in this model [21]. One of
these mutations relates to Asp102, the only potential N-glycosylation
site mutated in SHR. Given that this site is located within the fatty acid
binding pocket and, therefore, possibly important for the fatty acid
transport function, mutation of this site may explain the decrease in
fatty acid uptake upon pressure overload in this rat model. On the
other hand, total CD36 protein expression in SHR rats is greatly reduced,
perhaps due to mutation at the Asp102 residue or at one of the other
mutated sites, resulting in a decrease in its stability [21]. Hence, further
studies need to be undertaken to study the role of glycosylation in
altered fatty acid uptake in SHR.
In contrast to classical glycosylation, the modification of proteins
by O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic process
occurring in the cytoplasm and involving a reversible binding of a single
O-GlcNAc moiety to serine/threonine residues [22]. The process re-
quires two enzymatic activities to attach and to remove the O-GlcNAc
moiety, respectively. The attachment is mediated by O-GlcNAc transfer-
ase (OGT), and driven by the intracellular availability of O-GlcNAc formed
in the hexosamine biosynthesis pathway. CD36 has been proposed as
a target for O-GlcNAcylation [23]. Namely, glucosamine addition to per-
fused hearts increases both OGT binding to CD36, abundance of CD36 at
the sarcolemma, and fatty acid oxidation, leading the authors to conclude
that O-GlcNAcylation of CD36 induces CD36 translocation to the sarco-
lemma and subsequently enhances myocellular fatty acid uptake [23].
3. Acetylation of CD36
Proteomic analysis of lysine acetylation sites inmouse and rat tissues
revealed acetylation of CD36 at lysines 52, 166, 231, and 403 [24]. Acet-
ylation of these sites was confirmed by mass spectrometry analysis of
human CD36 [9], indicating that these acetylation sites are conserved
from rat to man. However, the dynamics and functional consequences
of these acetylations for CD36 expression and/or functioning have not
yet been investigated.
4. Phosphorylation of CD36
CD36 has at least two consensus phosphorylation sites, i.e., at Thr92
and Ser237, both of which are within the extracellular loop (Fig. 1). The
first site is a putative protein kinase C (PKC) site, and the second site is
recognized by protein kinase A (PKA) [25,26]. In resting platelets, theThr92 site is constitutively phosphorylated resulting in diminished
thrombospondin binding under non-stimulated conditions [25]. This
phosphorylation occurs in the Golgi on newly synthesized protein and
is retained upon trafficking of CD36 to the cell surface and subsequent
extracellular exposure of this site [27]. The other site is subject to
regulation by an ecto-kinase pathway involving PKA. In platelets,
CD36 ecto-phosphorylation inhibits fatty acid uptake in a reversible
manner [28]. Yet, this pathway may not be operative in heart and
muscle, as activation of PKA by isoproterenol, dibutyryl-cAMP or
the phosphodiesterase inhibitor amrinone did not influence fatty
acid uptake into cardiomyocytes [29]. Hence, in heart and muscle,
CD36 phosphorylation may be of only minor importance. Perhaps,
the ecto-kinase responsible for the inhibitory phosphorylation in
platelets is not present in the interstitial space in heart and muscle.
The CD36 phosphorylation status also appears regulated by phos-
phatases. In mouse small intestinal enterocytes, CD36 is co-localized
with global intestinal alkaline phosphatase, and de-phosphorylation
by this phosphatase resulted in increased fatty acid uptake [30]. These
data are in linewith the observations in platelets that CD36 phosphory-
lation is inhibitory for fatty acid uptake.
It is noteworthy to mention that phosphorylation processes are def-
initely linked to CD36 functioning and regulation of fatty acid utilization
in heart and muscle. First of all, phosphorylation of AMPK is critically
involved in vesicle-mediated CD36 translocation from endosomes to
the sarcolemma and contraction-stimulated fatty acid uptake [5].
Moreover, phosphorylation of Akt and AS160 are necessary for insulin-
stimulated CD36 translocation and increased fatty acid uptake [31,32].
Finally, CD36 is also known as a signaling hub upon binding to fatty
acids. This leads to phosphorylation of Src-protein-tyrosine kinases, par-
ticularly of Fyn and Yes and subsequent activation of calcium signaling
in gustatory cells [33]. In muscle, fatty acid-induced CD36-mediated Fyn
phosphorylation leads to AMPK activation, feeding forward to increased
fatty acid oxidation [34]. However, these mechanisms are outside the
scope of this review.
5. Ubiquitination of CD36
Ubiquitination of proteins is the coupling of proteins to ubiquitin (a
small protein of 8.5 kDa). Protein ubiquitination is generally considered
to trigger the degradation of these proteins through directing them to
proteasomes [35]. In short, there are threemain steps in ubiquitination:
activation, conjugation, and ligation, executed by ubiquitin-activating
enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin
ligases (E3), respectively. Substrate specificity is governed by E3, of
which there is a great variety. More recent investigations reveal that
several types of protein ubiquitination appear to exist, and the differ-
ent types have different impacts on their substrates. The classical
pathway targeting proteins for proteasomal degradation is the
poly-ubiquitination pathway linked to Lys48 on ubiquitin. On the
other hand, poly-ubiquitination linked to Lys63 on ubiquitin as well as
mono-ubiquitination are considered as non-degradative, and serve
other purposes, such as protein complex formation [36,37].
The first evidence that CD36 is a substrate for ubiquitination came
from studies in cell lines, including C2C12myotubes [38]. CD36 appears
to be constitutively poly-ubiquitinated involving both Lys48 and Lys63
linkage (Fig. 1). The degree of poly-ubiquitination was differentially
affected by exposure of cells to fatty acids or insulin: fatty acids increase
whereas insulin decreases the poly-ubiquitination of CD36. Concomi-
tantly, fatty acids reduce CD36 protein levels and decrease cellular
fatty acid uptake, and insulin has opposite effects. The degree of poly-
ubiquitination of CD36 did not affect the relative CD36 distribution
between intracellular storage compartments and cell surface [38].
Site-directed mutagenesis revealed that one or two lysines of CD36
located within the small intracellular C-terminal segment, i.e.,
Lys469 and Lys472, are responsible for this CD36 regulation by
poly-ubiquitination [38].
2256 J.J.F.P. Luiken et al. / Biochimica et Biophysica Acta 1862 (2016) 2253–2258More recently, it was found that CD36 is a target of Parkin, an E3
ligase. The malfunctioning of this enzyme is causally related to the
onset of Parkinson’s disease [39]. Livers of mice on a high-fat diet
displayed increased Parkin levels and increased CD36 levels as well
as increased lipid accumulation and insulin resistance [40]. In
Parkin-knockout mice, hepatic CD36 levels were markedly reduced
and the maladaptive responses towards a high-fat diet concerning
hepatic lipid levels and insulin signaling were completely blunted.
Parkin appeared to mono-ubiquitinate CD36 leading to an increase in
its stability [40]. It is expected that one of the intracellular C-terminal
lysines within CD36 is targeted by Parkin. Moreover, this lysine residue
could then be an integration point of the effects of fatty acids and Parkin
on CD36 [41]. Yet, this Parkin-mediatedmono-ubiquitination and stabi-
lization of CD36 in liver seems to conflict with the fatty acid-mediated
poly-ubiquitination and degradation of CD36 in cell lines. Namely,
Parkin expression is induced by fatty acids [40], so it is to be expected
that fatty acids should stabilize or increase the CD36 protein level rather
than decreasing it. A way out of this paradox is provided by the fact that
Parkin exhibits both mono- and poly-ubiquitination functions [42].
Hence, Parkin downstream effects can be proteasome-dependent
as well as independent. Perhaps the function of Parkin varies between
different tissues and/or circumstances, making it to operate as a
mono-ubiquitinase in one tissue under a specific condition and as a
poly-ubiquitinase in another tissue or in a different condition. Alterna-
tively, CD36 could be targeted by different, yet unidentified E3 ligases
in different tissues. Another controversial finding related to Parkin is
that this E3 ligase does not appear to be responsible for the increased
CD36 expression levels in the livers of aged mice on a high-fat diet, be-
cause Parkin levels were found to remain unaltered during ageing [43].
Finally, long-term incubation of HL1-cardiomyocytes or primary
rat cardiomyocytes with insulin and/or long-chain fatty acids did not
alter myocellular protein levels of CD36 [44,45], suggesting that CD36
ubiquitination does not occur in cardiomyocytes upon exposure to
either one or both stimuli. The latter observations underscore the notion
that the effects of E3 ligases on CD36 ubiquitination are strictly tissue-
specific.
6. Palmitoylation of CD36
There are several types of modification of proteins by lipids, among
which protein myristoylation (covalent attachment of a C14-fatty acid
group) and protein palmitoylation (covalent attachment of a C16-fatty
acid group) are most common [46,47]. In contrast to myristoylation,
which is considered to be an irreversible protein modification, the
palmitoyl moiety can be removed so that palmitoylation is compatible
with short-term regulation. The reversible covalent bond occurs
between palmitate and cysteine residues of proteins via a thioester link-
age in most cases, and less frequently to serine and threonine residues
of proteins [46,47]. In more detail, dynamic protein palmitoylation is
an enzymatic process, which requires palmitoyl-transferases (PATs)
and palmitoyl-protein thioesterases (PPTs) for palmitoylation and
depalmitoylation, respectively. Regarding the function of protein
palmitoylation, it is generally accepted that palmitoylation regulates
the subcellular localization,membrane interactions, as well as subcellu-
lar trafficking of proteins [46,47]. Remarkably, palmitoylation has no
obvious sequence requirements other than the cysteine residue, but
palmitoylation sites are often found in the proximity of transmembrane
segments.
The first reports that CD36 was palmitoylated came from studies
in adipocytes, in which CD36 appeared to be one of the major
palmitoylation targets, while this modification could be further increased
by insulin [48]. Palmitoylation occurs on the two N-terminal and two
C-terminal cysteines, in human CD36 corresponding to residues 3, 7,
464, and 468 [49]. Both cysteine pairs are intracellular and adjacent to
the transmembrane segments (Fig. 1). Mutation of the two N-terminal
cysteines into alanines and the two C-terminal cysteines into serinesdecreased the maturation of CD36 to the fully glycosylated form, which
was accompanied by a decrease in stability [50]. Also, a CD36 mutant in
which the four intracellular cysteines have been converted into serines
showed incomplete processing and decreased expression [51]. Yet, this
mutant, a C-terminal truncation mutant, or other CD36 mutants in
which either one or two of the cysteines were replaced by serines, each
showed proper localization at the cell surface in Chinese hamster ovary
(CHO) cells or HEK293 cells [49,51]. On the other hand, all four intracellu-
lar cysteines were observed to be needed for translocation of CD36 upon
insulin stimulation of CHO cells or stimulation by the AMPK activator
AICAR. However, immunoprecipitation experiments showed that
the 4*Cys→Ser-CD36 mutant was not differentially incorporated
with [3H]palmitate than wild-type CD36 in the absence or presence
of insulin, excluding the role of palmitoylation and suggesting that
another post-translational mechanism involving all four cysteines
is required for CD36 translocation [51]. In conclusion, palmitoylation
at its intracellular cysteines is necessary for CD36 maturation [50].
This palmitoylation could be mediated by Swf1, a member of the PAT
family, which is resident to the endoplasmic reticulum and responsible
for palmitoylation of many membrane proteins that are modified at
cytoplasmic cysteine residues close to the transmembrane domain [52].
7. Conclusions and perspectives
CD36 undergoes various types of post-translational modifications in
a tissue-, condition-, and time-dependent manner (Table 1). These
modifications each have distinct consequences for CD36 functioning
and, in addition, may show a specific interplay that together makes
the regulation of the functioning of CD36—for instance, in regulating
cellular fatty acid uptake—difficult to unravel. Phosphorylation may
regulate the fatty acid transport function of CD36, whereas N-linked
glycosylation, ubiquitination, and palmitoylation each affect CD36
expression and stability. In contrast, none of thesemodifications appear
to alter CD36membrane localization or function. TheN-linked glycosyl-
ation and palmitoylation processes occur as part of CD36 maturation in
the endoplasmic reticulum/Golgi and are therefore not likely to contrib-
ute to short-term regulation of fatty acid uptake in any tissue. Yet, CD36
ubiquitination by insulin occurs within a time frame of 30 min, giving
this modification type the ability to impact on fatty acid uptake at the
short-term level, as indeed has been shown [38].
CD36 translocation to the plasma membrane and subsequent
internalization (i.e., intracellular recycling) is a main determinant
of short-term regulation of myocellular fatty acid uptake by insulin or
AMPK activators, but the mechanisms underlying CD36 translocation
and internalization have been incompletely resolved. It is, however,
clear that most of the of the post-translational modification types,
i.e., glycosylation, phosphorylation, ubiquitination, and palmitoylation,
impacting on CD36 are not important for insulin-stimulated or AMPK-
mediated CD36 translocation. Only O-GlcNAcylation of CD36, as induced
upon stimulation of the hexosamine biosynthesis pathway, has been
shown to increase CD36 translocation, but this is independent of insulin
or AMPK activation [23].
Taking this a step further, it is possible that in the insulin-resistant or
diabetic heart, which shows elevated CD36 levels at the cell surface
and an increased rate of fatty acid uptake [5], CD36 undergoes increased
O-GlcNAcylation, and therefore increased translocation of CD36 to the
cell surface. This increased CD36 translocation then sets the stage for
further maladaptive lipid-induced alterations negatively impacting on
contraction force of cardiomyocytes [53]. Such hypothetical sequence
of events would be in line with earlier observations that there is
increased flux through the hexosamine biosynthesis pathway in insu-
lin-resistantmuscle [23].Moreover, in the diabetic heart, overall protein
O-GlcNAcylation has been increased and thismay be responsible for the
adverse effects of diabetes on cardiac function [54]. Anothermechanism
by which CD36 function is upregulated in diabetic tissues and possibly
contributes to high-fat diet-induced insulin resistance, is displayed by
Table 1
Reported effects of the various post-translational modifications of CD36 on its expression and functioning in cellular fatty acid uptake.
Post-translational modification type Tissue or cell type studied CD36-related parameters and cellular fatty acid uptake





N-linked glycosylation Various tissues and cell types ↑ n.k. – ↑
O-GlcNAcylation Heart – – ↑ ↑
Acetylation Various tissues n.k. n.k. n.k. n.k.
Phosphorylation Platelets, enterocytes n.k. ↓ – ↓
Poly-ubiquitination Muscle, adipose tissue ↓ – – ↓
Mono-ubiquitination Liver ↑ – – ↑
Palmitoylation Adipocytes, CHO cells ↑ – – ↑
Explanation of symbols: ↑, positive (stimulatory) effect; ↓, negative (inhibitory) effect; –, no effect; n.k., effect not known. Note that the implications of these post-translational modifications
were studied mostly in a particular tissue or cell model, so that extrapolation to other tissues or cell models may not apply. See text for more detailed explanation and literature references.
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upregulates CD36 and global intestinal alkaline phosphatase in
enterocytes, thereby increasing CD36-dependent fatty acid uptake [30].
Whether increased alkaline phosphatase action contributes to increased
cardiac fatty acid fluxes in the diabetic heart is not known. Besides these
examples of post-translational CD36 modifications increasing fatty acid
uptake, it should be investigated whether other post-translational
modifications of CD36 also occur in the insulin-resistant/diabetic heart
or in any other cardiac metabolic disorder. For instance, increased CD36
stabilization due to palmitoylation or to alterations in ubiquitination
could also lead to excessively increased fatty acid fluxes into the heart
and subsequent impairments in insulin signaling and contractile function.
Finally, other post-translational modifications, such as methylation,
isoprenylation, and sumoylation, might occur and could impact on CD36
but, to our knowledge, these have not yet been investigated. Therefore,
these additional modification types could be a topic for future studies.
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